Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocket Pharmaceuticals, Inc. (RCKT) on June 24, 2026. The report discloses changes in the Company's principal officers, specifically the resignation of the VP of Finance and the appointment of a new Principal Accounting Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: John Militello resigned as VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer, effective July 7, 2026.
- Appointment: Joseph Manhede was appointed as Principal Accounting Officer, effective July 8, 2026. He previously served as Associate Vice President, Corporate Controller since April 2026.
Management Commentary and Risks
Mr. Militello is departing to pursue other opportunities. Mr. Manhede brings significant experience from Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation, and Celator Pharmaceuticals, including roles in financial reporting, SEC compliance, and IPO readiness. No new compensatory arrangements were entered into for Mr. Manhede's new designation. The filing does not disclose specific risks, contingencies, or unusual items beyond the leadership transition.
Investor Verification Checklist
- Confirm the effective dates of the officer transitions (July 7 and July 8, 2026).
- Verify the interim status of the Treasurer and VP of Finance roles following Mr. Militello's departure.
- Review subsequent filings for any impact on internal controls or financial reporting timelines due to the change in Principal Accounting Officer.